BioPhorum introduces – Sustainability In conversation with Amgen

29 June 2022

In this interview, David Seitz, Director, Global Environment, Health, Safety and Sustainability, Amgen talks about taking inspiration from the air regulations and vehicle emissions improvements that saw the end to the LA ‘smog days’ of his childhood. How is Amgen making a difference to the current climate crisis, and does working with BioPhorum help in this process?

Sustainability for any organization is now mission-critical, moving from future-based commitments to practical action.  How is your organization connecting corporate strategy with operational execution?

We’ve been successfully executing formal sustainability plans since 2008. Our latest plan includes achieving Scope 1 & 2 carbon neutrality, reducing water by 40% and waste by 75% against our 2019 baseline. To achieve these 2027 goals, Amgen is focusing on the use of innovative approaches and processes, efficiency improvements, and increased sourcing of renewable energy.

In 2021, we included environmental, social, and governance (ESG) performance in our company goals under our annual executive compensation plan.

What are the biggest challenges you face as a sustainability leader?

There has been a significant increase in external and executive interest in ESG and ES.  I must learn all the emerging information, determine the relevance to Amgen and then educate internally and externally. I work closely with our corporate ESG team to ensure we are involved with the appropriate industry groups, like BioPhorum, so that we stay focused and help to drive change.

Also, there are many people who are passionate about sustainability in our organization.  I must balance my time between ensuring our critical sustainability efforts stay on track with coaching local resources and nurturing their enthusiasm.

What and/or who inspires you? Why? 

When I was a child in LA, we had smog days where we couldn’t go outside to play.  With the air regulations and vehicle emissions improvements, we don’t have this anymore. This is making a huge difference with the current and future generations.

What inspires me is that we’re making a difference at Amgen. I see the impact that climate change has caused in my lifetime, and it can feel overwhelming. Enabling projects that reduce water in our California locations for example, where water is scarce, or that convert our sales fleet to electric vehicles helps me sleep better at night.

Who are your key stakeholders and how do you keep them engaged?  

We have a robust governance process that extends from the working teams up to the CEO staff and Board of Directors.  We have a wide range of external disclosures—including our ESG report—to communicate frequently and transparently on our ESG performance.

If you could make one change that would make the greatest contribution to the development of a sustainable biologics industry, what would it be? 

I see the work that the biologics industry does in treating serious illnesses as very intertwined with sustainability. Access to clean water, clean air and life-saving medicines are foundational to a person’s health. This is one of the reasons that we changed one of our ESG pillars from “Environmental Sustainability” to “Healthy Planet.”  I would like others to make that same connection.

What do you hope to achieve working with BioPhorum Sustainability?

I look forward to collaborating with my peers in the biotech industry, sharing and standardizing best practices and educating other companies about adopting sustainability goals.  While our 2027 aspirations do not incorporate Scope 3 emissions, we are evaluating the carbon impact from our value chain—including suppliers, contract manufacturers, and distributors—to help identify reduction opportunities as we continue to pursue a responsible sourcing strategy. BioPhorum will be an excellent partner as we embrace this challenge across our industry.


2027 sustainability goals
Arrow On Colourful Background
Do you want to influence the future of long-range planning?
DNA pink background
Registering innovative raw materials using QbD principles: Protein A resins
Question Mark On Green Background
BioPhorum survey shows the scale of industry’s indirect carbon emissions challenge
Moving the industry toward a sustainable inbound supply chain of the future
BioPhorum Introduces – Sustainability in conversation with Ipsen

Advanced Therapy Medicinal Products

Advanced Therapy Medicinal Products support the quest for better and faster development of cell, gene and RNA therapies​ through connecting therapy developers, contract manufacturing, and testing organizations to gain an understanding and respond to the challenges faced by the advanced therapeutics industry.

Development Group

Development Group accelerates and improves the development process of biopharmaceutical medicines for the benefit of the patient. Replacing isolation with collaboration by providing a “safe” space where subject matter experts can work on sharing solutions and best practice on emerging industry trends, implementation of new technologies and common issues whilst ensuring their intellectual property and confidentiality is protected.

Drug Substance

Drug Substance advances excellence in drug substance manufacturing and testing, acting as an industry voice to accelerate technology adoption, implement post-approval change more rapidly and increase confidence in maintaining compliance.

Fill Finish

Fill Finish accelerates development and acceptance of sustainable world-class filling and packaging operations for drug product which meets the future needs of patients. Through innovative solutions resulting from the sharing of expertise, we can overcome common performance challenges and deliver on quality and regulatory compliance.

Information Technology

Information Technology accelerates digital maturity across the ​global pharmaceutical manufacturing industry.


BioPhorum Quality provides a dedicated, safe space for quality professionals from biomanufacturers and contract organizations to coalesce and enhance effective collaboration to address shared industry challenges.


Regulatory CMC brings leaders together who have a common goal – to improve access to medicines through innovation in the Regulatory ecosystem. It provides a dedicated space for strategic leadership and a coordinated industry voice, to move from divergence to convergence.

Supply Chain to Patient

Supply Chain to Patient transforms the performance of global pharmaceutical clinical and commercial outbound supply chains through industry collaboration by creating transparent patient-centric, resilient and agile E2E supply chains, that consistently deliver high-quality medicines ensuring an uninterrupted supply to patients.

Supply Partner

Supply Partner is a trusted advisory group and collaboration that is the engine for driving change across the global industry for all things relevant to the inbound supply chain. Addressing the challenges of complexity, resilience, cost, sustainability, and innovation.


Sustainability enables the industry’s transition to a low carbon, circular future – supporting members to improve patient health while respecting the planet. We activate multi-disciplinary teams drawn from our network to deliver environmental sustainability improvements across the value chain.

Technology Strategy

Technology Strategy acts as one voice of the industry to define strategy, accelerate technology transformation and support technology translation and adoption. With a purpose of enabling the future state of flexible, resilient, sustainable end-to-end biomanufacturing.

An industry perspective on understanding AAV capsid content variants
Needle On Yellow Background
An intercompany perspective on practical experiences of predicting, optimizing and analyzing high concentration biologic therapeutic formulations
The Drug Substance 2.0 Strategic Value Framework
Coloured dots on teal, next to vial
BioPhorum’s holistic approach to container closure integrity
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Inaugural BioPhorum Quality face to face – get involved
The next step in building regulatory as a capability to enable strategic innovation across the BioPhorum community
Delivering a Cell and Gene Therapy Outbound Supply Chain Pathway for the Industry
DNA and Earth on blue background
A vision for the biopharmaceutical industry’s inbound supply chain
A major milestone – a harmonized approach to product carbon footprint data
Technology Roadmap V 2.0
BioPhorum Technology Roadmapping roadmap vision 2.0


Documents including best practices, vision statements and peer reviewed papers to help you take value back to your business.


Discussing all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. Learn from the perspectives of those at the forefront of the industry.


BioPhorum Connect is our podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, these podcasts bring you the insights and perspectives of experts from around the world.


A variety of resources including design tools and user requirement specifications to help you improve and streamline your business processes.

Benchmarks and Surveys

Research conducted among the BioPhorum membership providing evidence to support change and identify best practice.

Browse all

Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.

Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Bioreactivity testing in single-use system biomanufacturing